TGA Extends Transition Period for ‘Permitted Indications’ List

Australia’s Therapeutic Goods Administration has extended the fee-free period for sponsors of existing listed medicines relisting under the agency’s Permissible Indications program. The fee-free period will now end on March 6, 2021.

The new program went into effect in March 2018 and included a three-year transition period for sponsors to re-list their products using permitted indications.

The agency said it extended the deadline to “minimize impacts on the industry and help ensure continued market access for transitioning listed medicines.”